Grufity logo
Grufity logo

Latest Patient Square Capital LP Stock Portfolio

$563Million | No. of Holdings #29

Patient Square Capital LP Performance

2026 Q1+11.12%
YTD+11.12%
2025+58.45%

About Patient Square Capital LP and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Patient Square Capital LP reported an equity portfolio of $563.6 Millions as of 31 Mar, 2026. <br><br> The top stock holdings of Patient Square Capital LP are ROIV, ARGX, INSM. The fund has invested 40.1% of it's portfolio in ROIVANT SCIENCES LTD and 4.8% of portfolio in ARGENX SE. <br><br> The fund managers got completely rid off TERNS PHARMACEUTICALS INC (TERN), LIQUIDIA CORPORATION (LQDA) and OCULAR THERAPEUTIX INC (OCUL) stocks. They significantly reduced their stock positions in SPYRE THERAPEUTICS INC (AGLE), INSMED INC (INSM) and DIANTHUS THERAPEUTICS INC. Patient Square Capital LP opened new stock positions in BELITE BIO INC (BLTE), LEGEND BIOTECH CORP (LEGN) and NEKTAR THERAPEUTICS (NKTR). The fund showed a lot of confidence in some stocks as they added substantially to HARROW INC (HROW), DBV TECHNOLOGIES S A (DBVT) and ARCUTIS BIOTHERAPEUTICS INC (ARQT).
Patient Square Capital LP Equity Portfolio Value
Last Reported on: 15 May, 2026
$563Million
  as of May 15, 2026

Patient Square Capital LP Annual Return Estimates Vs S&P 500

Our best estimate is that Patient Square Capital LP made a return of 11.12% in the last quarter. In trailing 12 months, it's portfolio return was 98.36%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
belite bio inc18,604,100
legend biotech corp17,909,100
nektar therapeutics15,109,500
merck & co inc9,623,200
definium therapeutics inc6,255,900
protara therapeutics inc5,370,710
cytomx therapeutics inc.5,103,210
New stocks bought by Patient Square Capital LP

Additions

Ticker% Inc.
harrow inc2,249
dbv technologies s a93.16
arcutis biotherapeutics inc90.78
cogent biosciences inc87.79
xenon pharmaceuticals inc66.3
perspective therapeutics inc43.45
argenx se41.22
beone medicines ltd16.2
Additions to existing portfolio by Patient Square Capital LP

Reductions

Ticker% Reduced
spyre therapeutics inc-99.33
insmed inc-41.01
dianthus therapeutics inc-37.41
enliven therapeutics inc-35.09
allogene therapeutics inc-30.5
kymera therapeutics inc-28.06
mirum pharmaceuticals inc-23.00
celcuity inc-20.83
Patient Square Capital LP reduced stake in above stock

Sold off

Ticker$ Sold
ocular therapeutix inc-5,948,600
amylyx pharmaceuticals inc-4,228,000
terns pharmaceuticals inc-12,928,000
avalo therapeutics inc-5,665,300
liquidia corporation-7,829,230
disc medicine inc-5,876,340
Patient Square Capital LP got rid off the above stocks

Sector Distribution

Patient Square Capital LP has about 78.8% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare78.8
Others21.2

Market Cap. Distribution

Patient Square Capital LP has about 50.7% of it's portfolio invested in the large-cap and mega-cap stocks.

  • LARGE-CAP
  • UNALLOCATED
  • MID-CAP
  • SMALL-CAP
  • MEGA-CAP
Category%
LARGE-CAP44.7
UNALLOCATED21.2
MID-CAP18.6
SMALL-CAP8.6
MEGA-CAP6

Stocks belong to which Index?

About 24.3% of the stocks held by Patient Square Capital LP either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
  • S&P 500
Index%
Others75.7
RUSSELL 200022.6
S&P 5001.7
Top 5 Winners (%)%
enliven therapeutics inc
127.4 %
dianthus therapeutics inc
84.3 %
ALLO
allogene therapeutics inc
66.2 %
perspective therapeutics inc
40.6 %
ROIV
roivant sciences ltd
27.6 %
Top 5 Winners ($)$
ROIV
roivant sciences ltd
49.0 M
enliven therapeutics inc
6.0 M
dianthus therapeutics inc
5.2 M
ALLO
allogene therapeutics inc
4.5 M
MIRM
mirum pharmaceuticals inc
3.5 M
Top 5 Losers (%)%
EYPT
eyepoint inc
-29.3 %
ASMB
assembly biosciences inc
-17.9 %
HROW
harrow inc
-16.9 %
abivax sa
-16.8 %
ARQT
arcutis biotherapeutics inc
-15.1 %
Top 5 Losers ($)$
EYPT
eyepoint inc
-4.2 M
ARGX
argenx se
-3.5 M
abivax sa
-3.0 M
INSM
insmed inc
-2.2 M
ARQT
arcutis biotherapeutics inc
-1.7 M

Patient Square Capital LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Patient Square Capital LP

Patient Square Capital LP has 29 stocks in it's portfolio. About 73.3% of the portfolio is in top 10 stocks. EYPT proved to be the most loss making stock for the portfolio. ROIV was the most profitable stock for Patient Square Capital LP last quarter.

$563.61MTotal Value
35.00Positions
15 May, 2026Last Reported
Current holdings of Current Stock Holdings of Patient Square Capital LP, last reported on 15 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ARGX
Argenx Se

Argenx Se

ARGX
Patient Square Capital LP's holding in Argenx Se over time
4.76%36,718
$26.81M
4.76%
increased 41.22 percentadded
BLTE
Belite Bio Inc

Belite Bio Inc

BLTE
Patient Square Capital LP's holding in Belite Bio Inc over time
3.3%116,684
$18.60M
3.3%
new position
DBVT
Dbv Technologies S A

Dbv Technologies S A

DBVT
Patient Square Capital LP's holding in Dbv Technologies S A over time
2.57%693,534
$14.49M
2.57%
increased 93.16 percentadded
LEGN
Legend Biotech Corp

Legend Biotech Corp

LEGN
Patient Square Capital LP's holding in Legend Biotech Corp over time
3.18%990,000
$17.91M
3.18%
new position